This study presents a genetically encodable, modular degradation platform that offers a novel intervention strategy for difficult-to-target membrane and secreted proteins, particularly suitable for developing therapeutics against targets that are challenging for traditional small-molecule drugs.
Literature Overview
The paper titled 'Endobody: Genetically Encodable Nanobody-CPP Chimeras for Degradation of Membrane and Extracellular Proteins,' published in the journal Advanced Science, systematically explores the construction of a novel, genetically encodable degrader—termed 'endobody'—by fusing nanobodies with cell-penetrating peptides (CPPs). This enables efficient degradation of membrane and extracellular proteins. The study not only validates the degradation efficacy in various cancer cell lines but also extends the approach to the hard-to-drug serum protein HE4. Furthermore, the authors designed bifunctional and enhanced endobodies, significantly improving degradation efficiency and applicability.Background Knowledge
Membrane proteins play critical roles in various diseases, such as EGFR in non-small cell lung cancer, HER2 in breast cancer, and PD-L1-mediated immune evasion, making them important therapeutic targets. However, traditional small-molecule inhibitors are often limited by the absence of binding pockets or the emergence of resistance mutations. While antibody drugs can target extracellular domains, they struggle to induce protein degradation. Current lysosome-based degradation technologies, such as LYTAC, rely on specific endocytic receptors (e.g., CI-M6PR), limiting their broad applicability across cell types. Moreover, many secreted proteins, such as HE4, lack transmembrane domains and cannot be targeted by conventional degradation strategies, rendering them long considered 'undruggable'.
The research focuses on leveraging the internalization capability of cell-penetrating peptides (CPPs) to bypass dependence on endocytic receptors, directly driving nanobody-antigen complexes into the endolysosomal system (ELS). This strategy offers a simple, genetically encodable platform without the need for chemical conjugation, opening a new path toward developing universal, programmable protein degradation systems.
Research Methods and Experiments
The authors first constructed an endobody, GBP-R9, using green fluorescent protein-binding protein (GBP) as a model. Confocal microscopy was used to observe its co-localization with EGFP-EGFR in live cells, confirming CPP-mediated internalization. Subsequently, a series of NbEGFR-CPP chimeras were generated using expressed protein ligation (EPL) technology. The degradation efficiency of cationic (R9, TAT), amphipathic (pVEC, Bac7), and hydrophobic (C105Y, Pep7) CPPs was systematically compared, revealing that R9 exhibited the strongest degradation activity. Using cell lines such as HeLa, MDA-MB-231, and SK-BR-3, the authors validated dose- and time-dependent degradation of EGFR, PD-L1, and HER2 by endobodies, which relied on the internalization function of R9.
To investigate the mechanism, the authors applied endocytosis inhibitors and found that only the clathrin-mediated endocytosis inhibitor Pitstop 2 blocked degradation, indicating that endobodies enter cells via a clathrin-dependent pathway. The lysosomal inhibitor Bafilomycin A1 completely suppressed degradation, while the proteasome inhibitor MG132 had no effect, confirming degradation depends on the ELS rather than the UPS pathway. For the extracellular protein HE4, the authors designed NbHE4-R9, successfully achieving degradation of serum HE4 in OVCAR3 cells and significantly inhibiting cell proliferation and migration.
To enhance degradation efficiency, the authors introduced a proteasome-targeting domain (PTD), constructing an enhanced endobody, EER9 P1 (2×NbEGFR-R9-PTD1). This design captures proteins that escape to the cytoplasm, enabling dual-pathway degradation via ELS and UPS. In vivo experiments in an A549 lung cancer xenograft model confirmed that EER9 P1 significantly suppressed tumor growth without notable toxicity.Key Conclusions and Perspectives
Research Significance and Prospects
This study introduces a novel tool for targeted degradation of membrane and secreted proteins, particularly valuable for 'undruggable' targets lacking small-molecule binding pockets. Its genetically encodable nature facilitates the development of gene therapy vectors suitable for sustained in vivo expression. Compared to platforms like LYTAC that require chemical conjugation, endobodies are easier to scale up and engineer.
Future work may explore additional CPP types, optimize PTD sequences, and design tissue-specific promoters to drive endobody expression, enhancing targeting and safety. Additionally, this platform can be used to construct bispecific or trispecific degraders for multi-pathway synergistic intervention, holding great promise in combination cancer immunotherapy.
Conclusion
The endobody platform proposed in this study represents a structurally simple, genetically encodable class of novel protein degraders, successfully achieving efficient degradation of membrane proteins such as EGFR, HER2, PD-L1, and secreted protein HE4. Its independence from endocytic receptors overcomes the cell-type limitations of technologies like LYTAC, while the PTD-enhanced design further boosts degradation efficiency. In terms of clinical translation, endobodies offer new therapeutic strategies for refractory cancers such as ovarian cancer (HE4-positive), non-small cell lung cancer (EGFR-mutant), and breast cancer (HER2-amplified). Their genetic encoding makes them suitable for AAV-mediated in vivo delivery, potentially evolving into long-acting gene therapies. Moreover, the design of bispecific endobodies provides a modular framework for multi-target synergistic treatment, which could be extended in the future to combined immune checkpoint degradation or tumor microenvironment remodeling. Overall, endobodies not only fill the technological gap in secreted protein degradation but also lay a solid foundation for next-generation targeted degradation therapies, potentially serving as a crucial bridge between basic research and clinical applications.
